Acro Biomedical (ACBM) Current Deferred Revenue (2017 - 2025)

Acro Biomedical has reported Current Deferred Revenue for 9 years, with the latest figure at $20000.0 in Q4 2025.

• On a quarterly basis, Current Deferred Revenue changed 0.0% year-over-year to $20000.0 in Q4 2025; TTM through Dec 2025 was $20000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $20000.0, changed 0.0% from the prior year.
• Current Deferred Revenue was $20000.0 for Q4 2025 at Acro Biomedical, roughly flat from $20000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $20000.0 in Q1 2021, with the low at $20000.0 in Q1 2021.
• Average Current Deferred Revenue over 5 years is $20000.0, with a median of $20000.0 recorded in 2021.
• The largest YoY upside for Current Deferred Revenue was 0.0% in 2021 against a maximum downside of 0.0% in 2021.
• Over 5 years, Current Deferred Revenue stood at $20000.0 in 2021, then changed by 0.0% to $20000.0 in 2022, then changed by 0.0% to $20000.0 in 2023, then changed by 0.0% to $20000.0 in 2024, then changed by 0.0% to $20000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $20000.0 (Q4 2025), $20000.0 (Q3 2025), and $20000.0 (Q2 2025), per Business Quant data.